生产企业：Leyden Laboratories B.V., RIGImmune
RIG-101 is an intranasal stem-loop RNA (SLR) therapeutic that agonizes RIG-I, triggering type I and type III interferon production in the respiratory epithelium. It is being developed by Leyden Labs, which acquired its originator RIGImmune in spring 2026, initially to prevent respiratory viruses from triggering asthma exacerbations. A completed Phase I study showed acceptable safety and on-target pharmacodynamic activity in healthy volunteers and asthma patients, and a two-part Phase I/II human rhinovirus RV-A16 challenge trial in adults with asthma is recruiting.
RIG-101 is an intranasal stem-loop RNA (SLR) therapeutic that agonizes RIG-I, triggering type I and type III interferon production in the respiratory epithelium. It is being developed by Leyden Labs, which acquired its originator RIGImmune in spring 2026, initially to prevent respiratory viruses from triggering asthma exacerbations. A completed Phase I study showed acceptable safety and on-target pharmacodynamic activity in healthy volunteers and asthma patients, and a two-part Phase I/II human rhinovirus RV-A16 challenge trial in adults with asthma is recruiting.
RIG-101 is an oligonucleotide of the stem-loop RNA therapeutic (SLR) class that agonizes RIG-I, a cytosolic innate immune receptor. Activation of RIG-I triggers type I and type III interferon production in the respiratory epithelium, priming innate antiviral defenses at the mucosal surface. In asthma patients, intranasal RIG-101 induced type I and type III interferons and upregulated interferon-stimulated genes in the upper respiratory tract, a pharmacodynamic signature consistent with the intended mechanism of action.
共 2 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
